Photo Credit: Getty Images
Antibiotics have long been hailed as lifesavers, but the rise of antibiotic-resistant "superbugs" is threatening this critical medical tool. These resilient bacteria are outsmarting drugs, leading to 1.14 million deaths globally in 2021 alone, according to *The Lancet*. India, one of the hardest-hit countries, reported around 300,000 deaths from resistant infections in 2019, with nearly 60,000 newborn fatalities annually.
However, a wave of innovation in India is offering hope. Chennai-based Orchid Pharma's Enmetazobactam became the first locally developed antibiotic to earn US FDA approval. This injectable drug targets bacteria's defense mechanisms, neutralizing enzymes like beta-lactamase that destroy antibiotics, allowing the treatment to work effectively. Trials in 19 countries confirmed its potency, particularly for critical infections like pneumonia and bloodstream infections.
Mumbai-based Wockhardt is also making strides with Zaynich, a groundbreaking antibiotic in Phase-3 trials. It has shown promise in treating drug-resistant infections, saving critically ill patients during compassionate-use cases. Another Wockhardt development, Nafithromycin (MIQNAF), is a three-day oral treatment for bacterial pneumonia, showing a 97% success rate in trials.
Despite these advancements, challenges remain. A 2023 Indian Council of Medical Research (ICMR) report revealed alarming resistance trends in pathogens like *E.coli* and *Klebsiella pneumoniae*. Last-resort antibiotics, such as carbapenems, are becoming less effective, underscoring the need for better drug stewardship and reduced misuse of broad-spectrum antibiotics.
Experts stress a holistic approach, including better hygiene, vaccination, and physician education, to combat this crisis. "Without urgent action, even minor infections could become untreatable," warns Dr. Kamini Walia of ICMR.
